Elkfork Partners’s Agios Pharmaceuticals AGIO Stock Holding History

Elkfork Partners’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$29K	Buy	902 +616	+215%	+$25.5K	﹤0.01%	1010
2019 Q2	$14K	Sell	286 -4,026	-93%	-$215K	﹤0.01%	1039
2019 Q1	$291K	Buy	4,312 +1,276	+42%	+$74.3K	0.01%	710
2018 Q4	$140K	Buy	3,036 +2,882	+1,871%	+$178K	﹤0.01%	843
2018 Q3	$12K	Sell	154 -286	-65%	-$23K	﹤0.01%	1007
2018 Q2	$37K	Buy	440 +396	+900%	+$34.5K	﹤0.01%	982
2018 Q1	$4K	Buy	+44	New	+$3.4K	﹤0.01%	1022

Other funds holding AGIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Elkfork Partners's AGIO Position: Q3 2019 in Review

Elkfork Partners increased its Agios Pharmaceuticals (AGIO) stake by 215% in Q3 2019, buying an estimated $25.5K and bringing the position to 902 shares worth $29K. The position accounts for ﹤0.01% of the portfolio, ranked #1010.

Elkfork Partners first reported a position in AGIO in Q1 2018 and has held it in 7 quarters since. The position peaked at $291K in Q1 2019. 189 funds tracked by Wall St. Rank hold AGIO as of Q3 2019.

Elkfork Partners held 902 shares of Agios Pharmaceuticals worth $29K as of Q3 2019.
Elkfork Partners bought 616 Agios Pharmaceuticals shares in Q3 2019, an estimated $25.5K.
Agios Pharmaceuticals made up ﹤0.01% of Elkfork Partners's portfolio in Q3 2019, its #1010 holding.
Elkfork Partners first reported a position in Agios Pharmaceuticals in Q1 2018 and has held it in 7 quarters since.
Elkfork Partners's Agios Pharmaceuticals position peaked at $291K in Q1 2019.
189 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.